Table 2

%Hematological toxicity: worst toxicity per patient at each dose level

Dose level (g/m2)No. of patientsNo. of CD34+ cells reinfused (no./kg b.w.); mean (range)WBC nadira below 0.5 × 109/literThrombocyte nadira below 25 × 109/liter
Median (days)Range (days)Median (days)Range (days)
20.042.15 (1.7–2.8)0000–1b
26.032.50 (1.6–4.6)00–100–1
32.535.33 (2.3–11.2)21–331–10c
39.031.80 (1.1–2.7)22–330–3
47.035.90 (3.4–8.4)43–421–3
56.062.59 (1.3–3.4)33–10d21–7d
  • a Transplantation of autologous PBSC at day 0.

  • b Patient 3 died 10 days after autologous PBSCT because of rapid progression of metastatic yolk sac tumor (18 × 109/liter platelets at day 10).

  • c Patient 10 (Hodgkin’s disease) died 19 days after autologous PBSCT because of fungal sepsis despite hematological recovery.

  • d Patient 20 (multiple myeloma) was heavily pretreated including radiotherapy and previous autologous PBSCT.